相关实验视频
Updated: May 11, 2025

07:42
Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity
Published on: April 26, 2012
18.1K
神经瘤学中的偶然性:化疗剂的演变
Denise Nadora1, Shawyon Ezzati1, Brandon Bol1
1College of Medicine, California Northstate University, Elk Grove, CA 95757, USA.
International journal of molecular sciences
|April 17, 2025
概括
神经瘤学药物发现面临挑战,有针对性的疗法显示有限的成功. 与理性设计一起接受偶然性可能会改善脑瘤治疗的结果.
科学领域:
- 神经瘤学神经瘤学
- 药物发现 药物发现 药物发现
- 翻译医学是一种翻译医学.
背景情况:
- 开发用于脑瘤,特别是质瘤的新疗法具有挑战性.
- 向治疗由于瘤的复杂性,导致临床成功有限.
- 高成本和低成功率是神经瘤学药物开发的特征.
研究的目的:
- 批判性地检查神经瘤学药物发现的景观.
- 突出偶然性在识别有影响力的疗法中的作用.
- 建议将偶然发现与理性设计相结合,以提高成功率.
主要方法:
- 历史和当代神经瘤学药物发现案例的审查.
- 分析了重定向药物或非目标效应带来好处的情况.
- 检查偶然发现对治疗发展的影响.
主要成果:
- 针对特定途径的合理药物设计已经显示出稀疏的临床成功.
- 偶然的发现,包括重新定位的药物和有益的非目标效应,导致了突破.
- 机会在开发具有影响力的神经瘤治疗中发挥了重要作用.
结论:
- 脑瘤的复杂性需要探索各种发现途径.
- 将偶然性与合理的药物设计相结合,可能会加速神经瘤学的进展.
- 未来的神经瘤学治疗开发可能会从接受意想不到的发现中受益.
相关概念视频
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Cancer Therapies
7.4K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.4K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Treatment Resistant Cancers
3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
Drug Discovery: Overview
7.1K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.1K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
137
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
137

